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Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenoﬁbrate reduces blood pressure and sodium retention
during DOCA-salt hypertension. PPAR-α activation reduces the expression of inﬂammatory cytokines, such as interleukin-
6 (IL-6). Fenoﬁbrate also induces cytochrome P450 4A (CYP4A) and increases 20-hydroxyeicosatetraenoic acid (20-HETE)
production. This study tested whether the administration of fenoﬁbrate would reduce blood pressure by attenuating plasma
IL-6 and renal expression of cyclooxygenase-2 (COX-2), while increasing expression of renal CYP4A during 7 days of DOCA-
salt hypertension. We performed uni-nephrectomy on 12–14 week old male Swiss Webster mice and implanted biotelemetry
devices in control, DOCA-salt (1.5mg/g) treated mice with or without fenoﬁbrate (500mg/kg/day in corn oil, intragastrically).
Fenoﬁbrate signiﬁcantly decreased mean arterial pressure and plasma IL-6. In kidney homogenates, fenoﬁbrate increased CYP4A
and decreased COX-2 expression. There were no diﬀerences in renal cytochrome P450, family 2, subfamily c, polypeptide 23
(CYP2C23) and soluble expoxide hydrolase (sEH) expression between the groups. Our results suggest that the blood pressure
lowering eﬀe c to fP P A R - α activation by fenoﬁbrate involves the reduction of plasma IL-6 and COX-2, while increasing CYP4A
expression during DOCA-salt hypertension. Our results may also suggest that PPAR-α activation protects the kidney against renal
injury via decreased COX-2 expression.
1.Introduction
Peroxisome proliferator-activated receptor-alpha (PPAR-α)
activation has been implicated in blood pressure regulation
and diﬀerent models of hypertension [1–6]. During DOCA-
salt-induced hypertension, activation of PPAR-α increases
renal tubular cytochrome P450 4A (CYP4A) expression,
thereby increasing 20-hydroxyeicosatetraenoic acid (20-
HETE) production which aﬀects sodium retention and re-
duces blood pressure. PPAR-α deﬁciency blocks these eﬀects,
suggesting the dependency on PPAR-α [6]. PPAR-α has been
found to colocalize with arachidonate CYP450 4A enzymes
in the renal proximal tubule and P450 4A monooxygenases
are known PPAR-α target genes [7] .Ap r e v i o u sr e p o r ta l s o
demonstrates PPAR-α activation exerts protective actions
during DOCA-salt-induced hypertension via mechanism
that involves nitric oxide production and/or inhibition
of NAD(P)H oxidase activity and reduced generation of
reactive oxygen species (ROS) [8]. PPAR-α activation has
also been shown to increase nitric oxide generation and
promote renal excretion of Na+ through reduced Na+-
K+ ATPase in the proximal tubule [9]. Therefore, PPAR-α
plays an important role of regulating blood pressure during
hypertension.
Peroxisome proliferator-activated receptor-alpha (PPAR-
α) activation plays a major role in the regulation of vascular2 PPAR Research
inﬂammation [10, 11]. Proinﬂammatory cytokines have
been implicated in the pathogenesis of hypertension [12–
14]. PPAR-α deﬁciency has resulted in elevated expression of
nuclear factor- κB( N F - κB), an important pro-inﬂammatory
transcription factor [15] .F e n o ﬁ b r a t e ,aP P A R - α agonist,
has been shown to decrease monocyte release of numer-
ous cytokines, including interleukin-6 (IL-6), monocyte
chemoattractant protein-1 (MCP-1), lymphocyte release of
interleukin-2, interferon-γ,a n dt u m o rn e c r o s i sf a c t o r - α
(TNF-α), which was accompanied by a decrease in plasma
C-reactive protein levels [16]. IL-6 has been shown to play a
major role in the hypertension of human and animal models
[12, 17, 18]. DOCA-salt hypertension causes an increase in
renalIL-6,TNF-α,MCP-1,endothelin-1,andreactiveoxygen
species[19].Previousresultsalsodemonstratethatﬁveweeks
of administering fenoﬁbrate signiﬁcantly attenuated IL-6,
cyclooxygenase-2 (COX-2), vascular cell adhesion molecule-
1, and MCP-1, reduced myocardial ﬁbrosis, and prevented
the development of diastolic function during DOCA-salt
treatment. It was concluded that the ﬁve-week treatment
with fenoﬁbrate was mediated partly by prevention of
inﬂammatory mediators through the NF-kappa-B pathway
[20]. Recombinase-activating gene (RAG-1) knockout mice,
which lack both T and B lymphocytes, show a blunted
hypertensive response during DOCA-salt hypertension [21].
A previous study also demonstrates plasma levels of IL-6
are elevated on day 7 of DOCA-salt-induced hypertension
[22]. Therefore, the goal of this study was to determine
if PPAR-α activation during 7-day treatment of DOCA-
salt lowered blood pressure through anti-inﬂammatory
mechanisms by reducing COX-2 expression in the kidney
and lowering plasma IL-6, as well as increasing renal CYP4A
expression.
2. Methods
2.1. Telemetry. Procedures involving animals were approved
by the Animal Care and Use Committee of Howard Univer-
sity. The experiments were conducted on 12-to 14-week-old
Swiss Webster (28–32g) male mice that were divided into
three groups (control, DOCA-salt, and DOCA-salt + fenoﬁ-
brate, n = 7–8 per group). The animals were anesthetized
using isoﬂurane, and biotelemetry transmitter devices (PA-
C10, Data Sciences, St. Paul, MN) were implanted using
aseptic technique. The catheter was implanted in the left
carotid artery through an incision in the vessel wall made
with a custom-shaped 27.5-gauge needle. The body of the
transmitter was tunneled subcutaneously above the right
shoulder and secured above the scapula. The left kidney
was removed from all mice through a ﬂank incision during
the transmitter surgery. All incisions were inﬁltrated with
1% lidocaine and mice were placed in warm cages to
recover following surgery. The mice were transferred to
a light- and temperature-controlled room in the animal
facilities and were housed individually in standard mouse
cages with tap water and standard rodent chow available ad
libitum. The mice were given 7-days to recover from surgery
before control measurements were made. Baseline mean
arterial pressure and locomotor activity were collected for
3 days. After the collection of baseline data, a DOCA pellet
(1.5mg/g, Innovative Research of America, Sarasota, FL)
was implanted subcutaneously for seven-days. The dose of
DOCA treatment was similar to the dosage used in previous
studies [6, 22]. All mice were given a drinking solution of 1%
NaCl and 0.1% KCl. Mice treated with fenoﬁbrate were given
a dose of 500mg/kg/day in corn oil, intragastrically (ig). A
previous report used the same dose for a diﬀerent PPAR-
α agonist (cloﬁbrate) during DOCA-salt hypertension [6].
Mean arterial pressure and locomotor activity were recorded
19-hours/day for a total of 10 days. On day 7 of DOCA-salt,
micewereanesthetizedwithisoﬂurane,andblood,heart,and
kidney were harvested.
2.2. Plasma IL-6 Concentration. Plasma IL-6 concentrations
were measured by enzyme immunoassay (R&D Systems,
Minneapolis, MN) from terminal femoral artery blood
samples obtained on day 7 of DOCA treatment. Animals
from all groups were included on the same assay plate to
control for interassay variability.
2.3. Urinary Albumin Concentration. Albumin concentra-
tion was measured from a one day timed urine collection on
control day 7, DOCA and DOCA + fenoﬁbrate day 7, using
an Albuwell murine microalbuminuria ELISA (Exocell).
2.4. Mouse Cytokine Array. A mouse cytokine array (R&D
Systems, Minneapolis, MN) was used to determine protein
expression of the inﬂammatory cytokines. Plasma samples
from the control, DOCA-salt, and DOCA + fenoﬁbrate
were collected using heparin as an anticoagulant. Plasma
samples were centrifuged for 20 minutes at approximately
2000× g within 30 minutes of collection. Plasma samples
were combined with array buﬀers, aspirated over the well
multidishes and incubated overnight. After multiple washes,
well multi-dishes were incubated with Streptavidin-HRP.
Images were analyzed by using the NIH imaging software,
Image J. Pixel density for each inﬂammatory cytokine was
normalized against the respective positive control on each
well multidish. Data are expressed as a percent change.
2.5. Western Blot. Whole kidney homogenized protein sam-
ples (50μg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on a 10% Tris-glycine
gel, and proteins were transferred electrophoretically to a
PVDF membrane. Non-speciﬁc binding sites were blocked
by incubating the blots overnight at 4◦C in a Tris-NaCl
buﬀer (TBS) containing 5% nonfat dry milk and 0.1%
Tween 20. The primary antibodies used are rabbit CYP2C23,
CYP4A,sEH,(1:1000;SantaCruz,CA)andCOX-2(1:1000,
Cayman Chemical). The blots were then washed in a TBS-
0.1% Tween and incubated with the secondary antibody
goat anti-rabbit 1:5000 and goat anti-mouse 1:10000 for
β-actin) conjugated to horseradish peroxidase for 1 hour
and washed. Detection was accomplished using enhanced
chemiluminescence western blotting, and band intensity was
measured densitometrically and the values were normalized
to β-actin.PPAR Research 3
2.6. Statistical Analysis. Mean arterial pressure data were
analyzed with a repeated measure ANOVA. Signiﬁcant F-
test from the ANOVA at P<0.05 was followed by post
hoc comparisons using the Newman-Keuls multiple range
test. A one-way ANOVA was used to analyze additional
parameters with the Krusal-Wallis post hoc test. Signiﬁcance
was considered at P<0.05.
3. Results
Figure 1 shows mean arterial pressure of control, DOCA-
salt and DOCA-salt + fenoﬁbrate treated mice. Baseline
mean arterial pressure was not diﬀerent between the groups.
DOCA-salt treatment had a signiﬁcant hypertensive eﬀect
when compared to control mice. The initial increase in mean
arterial pressure was also similar in the DOCA and DOCA-
salt + fenoﬁbrate groups. The administration of fenoﬁbrate
resulted in a signiﬁcant decrease in mean arterial pressure on
days4–7ofDOCA-salttreatment.Themeanarterialpressure
in the DOCA-salt + fenoﬁbrate treated group returned
to near baseline levels by day 7 of DOCA-salt treatment.
DOCA-salt + fenoﬁbrate and control mice MAP were not
diﬀerent on days 6-7. Figure 2 shows the kidney and heart
weight to body weight ratios in control, DOCA-salt treated
andDOCA-salt+fenoﬁbratetreatedmice.AlthoughDOCA-
salt slightly increased and DOCA-salt + fenoﬁbrate slightly
decreasedthekidneyandheartweightstobodyweightratios,
there were no signiﬁcant diﬀerences between the kidney and
heart weight to body weight ratios of the control, DOCA-
salt and DOCA-salt + fenoﬁbrate treated groups. There were
also no signiﬁcant diﬀerences in locomotor activity of the
control, DOCA-salt and DOCA-salt + fenoﬁbrate treated
groups (data not shown).
Our initial investigation of plasma cytokines during
DOCA-salt treatment involved the utilization of a mouse
cytokine array to determine changes in plasma samples
during the seven-day period of DOCA-salt hypertension.
The preliminary results from the mouse cytokine array
revealed a 30 ± 7% increase in plasma expression of IL-6
in DOCA-salt treated mice when compared to the DOCA-
salt + fenoﬁbrate group. Plasma expression of IL-6 in control
and DOCA-salt + fenoﬁbrate treated groups were similar
(data not shown). We did not see signiﬁcant diﬀerences in
MCP-1 or TNF-α plasma expression between the DOCA-
salt and DOCA-salt + fenoﬁbrate groups. Therefore, we later
performed an IL-6 enzyme immunoassay to determine the
concentrationofIL-6intheplasmaofallgroups.InFigure 4,
our plasma IL-6 results on day 7 of DOCA-salt hypertension
illustrate that fenoﬁbrate caused a signiﬁcant reduction in
plasma IL-6, when compared to DOCA-salt alone. Plasma
IL-6 levels were not diﬀerent between the control and
DOCA-salt + fenoﬁbrate treated groups (Figure 3).
Whole kidney homogenates were used to determine
COX-2, CYP4A, soluble expoxide hydrolase and CYP2C23
expression during DOCA-salt treatment. Fenoﬁbrate treat-
ment during DOCA-salt hypertension signiﬁcantly reduced
COX-2 renal expression when compared to DOCA-salt
alone. However, fenoﬁbrate did not return COX-2 renal
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Figure 1: Mean arterial pressure during a seven-day treatment
period in control mice, DOCA-salt-treated (1.5mg/g) group and
a DOCA + fenoﬁbrate-treated (500mg/kg/day) group. C: control
days, D: DOCA salt days (∗P<0.05).
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Figure 2: Kidney- and heart-weight-to-body-weight ratios in
control, DOCA-salt-treated,andDOCA + fenoﬁbrate-treated mice.4 PPAR Research
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Figure 3: Plasma interleukin-6 on day seven of DOCA-salt
hypertension in control, DOCA and DOCA + fenoﬁbrate-treated
mice (∗indicates DOCA signiﬁcantly increased plasma IL-6 when
compared to control and DOCA + fenoﬁbrate; P<0.05).
expression back to control levels. Fenoﬁbrate treatment also
signiﬁcantly increased CYP4A when compared to DOCA-
salt and control groups. No diﬀerences were observed in the
renal expression of sEH and CYP2C23 between the groups
(Figure 4).
Renal injury was assessed on day 7 of DOCA-salt hyper-
tension by measuring 24-hour albumin excretion. DOCA-
salt hypertension signiﬁcantly increased microalbuminuria
on day 7 and fenoﬁbrate signiﬁcantly reduced albumin
excretion. There was no signiﬁcant diﬀerence of albumin
excretion between control and DOCA + fenoﬁbrate-treated
mice (Figure 5).
4. Discussion
The results from this study demonstrate that the PPAR-α
agonist fenoﬁbrate causes a signiﬁcant reduction in blood
pressure during a 7-day model of DOCA-salt hypertension
by signiﬁcantly reducing plasma IL-6 and increasing CYP4A
expression in the kidney. We further show that fenoﬁbrate
also caused a signiﬁcant reduction in renal COX-2 expres-
sion. Our results also demonstrate that in our 7-day model
of DOCA-salt hypertension, fenoﬁbrate did not cause a
signiﬁcant reduction in heart- and kidney-weight-to-body-
weight ratios. Therefore, on the basis of these and previous
ﬁndings, we hypothesize that the activation of PPAR-α with
the agonist fenoﬁbrate, during a 7-day model of DOCA-
salt hypertension causes a reduction in blood pressure via
ananti-inﬂammatoryanddirectrenalmechanisms.Previous
results demonstrate that bezaﬁbrate [23]a n dc l o ﬁ b r a t e[ 6],
inducers of CYP4A and 20-HETE have been shown to
decrease blood pressure in DOCA-salt hypertensive mice.
In addition, the COX-2 inhibitor, SC58236, reduced renal
inﬂammationandinjuryofdiabeticDOCA-salthypertensive
rats independent of blood pressure lowering eﬀects [24]. In
the current study, we extend the blood pressure lowering
observations of the inducers of CYP4A and 20-HETE, to
demonstrate that fenoﬁbrate may also reduce blood pressure
through IL-6-dependent mechanism.
Previous results demonstrate that plasma IL-6 is signif-
icantly elevated on day 7 of DOCA-salt hypertension and
decreases to baseline levels on day 14 with no signiﬁcant
reduction in blood pressure. In addition, DOCA-salt treat-
ment in IL-6 KO mice demonstrated that mineralocorticoid
hypertension does not require IL-6 [22]. Therefore, it is
hypothesized that increases in plasma IL-6 are not needed
for blood pressure elevation after day 7 of DOCA-salt
hypertension. The present study goal was to determine if
the increase in plasma IL-6 on day seven of DOCA-salt
hypertension plays a major role in the blood pressure ele-
vation. Our goal was to also determine if PPAR-α activation
would decrease inﬂammatory markers and promote renal
regulation of blood pressure through a CYP4A and 20-
HETE pathway. Our results suggest that during a 7-day
model of DOCA-salt hypertension, IL-6 plays a major role in
blood pressure regulation. Additional studies are needed to
determine which inﬂammatory markers are elevated during
a 7-day model of DOCA-salt hypertension in the absence of
plasma IL-6. Results from our cytokine array suggest that
plasma levels pro-inﬂammatory cytokines TNF-α and MCP-
1 were not signiﬁcantly diﬀerent between DOCA-salt and
DOCA-salt + fenoﬁbrate groups and may not contribute to
blood pressure diﬀerences in our acute model of DOCA-
salt hypertension. In addition, future studies are needed
to determine if the role of IL-6 on blood pressure during
DOCA-salt hypertension is diﬀerent in Swiss Webster mice
used in this study and C576BL6 used in previous studies
[19, 22].
A previous study demonstrates DOCA-salt hypertension
causes an increase in inﬂammatory markers, including renal
TNF-α, MCP-1, and IL-6 [19]. Previous results also demon-
strate that COX-2 expression is increased in a model of
DOCA-salt hypertension [25, 26]. In an experimental model
ofdiabetesandDOCA-salthypertension,inhibitionofCOX-
2 expression decreases potential mediators of glomerular
and tubulointerstitial injury and also decreases biochemical,
functional, and structural markers of renal injury [24].
PPAR-α activation has also been shown to blunt renal
damage that is characteristic of DOCA-salt hypertension [8].
Previous results also show that COX-2 expression increases
during DOCA-salt hypertension and mediates production
of factors that enhances vasoconstriction [25]. Our results
demonstrate that PPAR-α activation with fenoﬁbrate caused
a signiﬁcant decrease in renal COX-2 expression. Our results
may also suggest that PPAR-α activation during a seven-day
model of DOCA-salt hypertension decrease markers of renal
injury.
Cytochrome P450 (CYP) 4A gene catalyzes the synthesis
of 20-HETE. In renal tubular segments, 20-HETE is an
important mediator in the regulation of sodium trans-
port. Previous results demonstrate that increased 20-HETE
production by PPAR-α activation is also involved in the
regulation of blood pressure and sodium retention in a
DOCA-salt model. More speciﬁcally, sodium retention was
associated with reduced renal 20-HETE production [6].
The previous report also demonstrates that treating DOCA-
salt mice with cloﬁbrate, a PPAR-α agonist, attenuated the
increase in mean arterial pressure and cumulative sodiumPPAR Research 5
DOCA DOCA + Fen
0
0.3
0.6
0.9
1.2
R
e
n
a
l
 
C
O
X
2
 
e
x
p
r
e
s
s
i
o
n
/
β
-
a
c
t
i
n
COX2
β-actin
Control
DOCA DOCA + Fen Control
(a)
0
0.3
0.6
0.9
1.2
β-actin
R
e
n
a
l
 
C
Y
P
4
A
 
e
x
p
r
e
s
s
i
o
n
/
β
-
a
c
t
i
n
DOCA DOCA + Fen Control
DOCA DOCA + Fen Control
CYP4A
(b)
0
0.3
0.6
0.9
1.2
1.5 β-actin
R
e
n
a
l
 
C
Y
P
2
C
2
3
 
e
x
p
r
e
s
s
i
o
n
/
β
-
a
c
t
i
n
DOCA DOCA + Fen Control
DOCA DOCA + Fen Control
CYP2C23
(c)
0
0.3
0.6
0.9
1.2
1.5
R
e
n
a
l
 
s
E
H
 
e
x
p
r
e
s
s
i
o
n
/
β
-
a
c
t
i
n
β-actin
DOCA DOCA + Fen Control
DOCA DOCA + Fen Control
sEH
(d)
Figure 4: Western blot expression and analysis of (a) COX-2, (b) CYP4A, (c) CYP2C23, and (d) sEH in whole-kidney homogenates
taken from control, DOCA, and DOCA + fenoﬁbrate mice (∗indicates DOCA + fenoﬁbrate signiﬁcantly reduced COX-2 expression when
compared to DOCA alone. / =indicates DOCA + fenoﬁbrate COX-2 expression was signiﬁcantly higher than the control group. ∗indicates
DOCA and DOCA + fenoﬁbrate have signiﬁcantly diﬀerent renal CYP4A expression when compared to control. / =indicates DOCA +
fenoﬁbrate renal expression of CYP4A is signiﬁcantly increased when compared to DOCA (P<0.050)).
balance while increasing 20-HETE production and renal
CYP4A expression [6]. Previous reports also demonstrate
that PPAR-α agonists benzoﬁbrate [27] and fenoﬁbrate [3]
increases renal CYP4A expression in mice and cause a
signiﬁcant reduction in blood pressure during DOCA-salt
and angiotensin II hypertension, respectively. In the present
study, our results also suggest that a seven-day treatment of
DOCA-salt increases renal CYP4A expression during fenoﬁ-
brate treatment and cause, antihypertensive mechanisms
that may involve an increase in 20-HETE production.6 PPAR Research
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Figure 5: Urinary albumin excretion on day seven in control,
DOCA, and DOCA + fenoﬁbrate-treated mice. ∗indicates DOCA
albumin excretion is signiﬁcantly diﬀerent from control and DOCA
+ fenoﬁbrate-treated mice.
Soluble epoxide hydrolase (sEH) contributes to hyper-
tension [28], inﬂammation, and renal injury [29]. Reduction
in renal inﬂammation and injury was observed in a 21-
day model of DOCA-salt hypertension with the use of a
sEH inhibitor, demonstrating that the C-terminal hydrolase
domainofthesEHenzymeisresponsibleforrenalprotection
with DOCA-salt hypertension [29]. Our results demonstrate
that treatment with the PPAR-α agonist, fenoﬁbrate, did
not reduce sEH during a seven-day model of DOCA-salt
hypertension. Although CYP2C23 is the main epoxygenase
that drive epoxyeicosatrienoic acids production to produce
vasodilatory metabolites that are antihypertensive and anti-
inﬂammatory eﬀects [30], we did not observe a signif-
icant eﬀect of fenoﬁbrate on renal CYP2C23 expression
in our seven-day model of DOCA salt hypertension. Our
results and previous studies suggest sEH and CYP2C23
contribute to the hypertension after 7-days of DOCA-salt
treatment.
In summary, the current study demonstrates that PPAR-
α agonist fenoﬁbrate causes a reduction in blood pres-
sure during a 7-day model of DOCA-salt hypertension by
reducing renal COX-2 and increasing CYP4A expression
while decreasing plasma levels of IL-6. The ability of
ﬁbrates to induce CYP4A and increased 20-HETE pro-
duction could be a potential treatment for salt-sensitive
hypertension. In addition, PPAR-α modulates the renin-
angiotensin-aldosterone system, a major regulator of sys-
temic blood pressure and interstitial ﬂuid volume by tran-
scriptional control of renin, angiotensin, angiotensin con-
verting enzyme, and angiotensin II receptor [31]. Therefore,
PPAR-α activation can cause a signiﬁcant reduction in
blood pressure through direct renal and anti-inﬂammatory
mechanisms during a short-term model of DOCA-salt
hypertension.
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